Bloomberg
Lilly to Buy Merida for $2.88B in Autoimmune Push
Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Eli Lilly plans to buy Merida Biosciences Inc. for as much as $2.88 billion in cash to expand in autoimmune and allergic diseases, part of an effort to build beyond the…
View original source — Bloomberg ↗
Related stories
Bloomberg
BusinessSep 2, 2026 · 1 min
Pets, Health & Wellness Seen As Top Consumer Investments
Bloomberg
CNBC
HealthJun 9, 2026 · 1 min
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
CNBC
Financial Times
HealthJun 9, 2026 · 1 min
GSK in talks to buy cancer biotech Nuvalent for more than $9bn
Financial Times
Bloomberg
HealthJun 9, 2026 · 1 min
GSK Agrees to Buy Nuvalent for $10.6 Billion
Bloomberg